RECK antibody (AA 179-806)

Catalog No. ABIN7871358

The Rabbit Polyclonal anti-RECK antibody is suitable to detect RECK in samples from Human, Mouse and Rat. It has been validated for WB, ELISA and FACS.

Quick Overview for RECK antibody (AA 179-806) (ABIN7871358)

Target: RECK (Reversion-Inducing-Cysteine-Rich Protein with Kazal Motifs (RECK))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This RECK antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Flow Cytometry (FACS)

Product Details anti-RECK Antibody

Binding Specificity: AA 179-806

Purpose: RECK Antibody / Reversion-inducing cysteine-rich protein with Kazal motifs

Purification: Immunogen affinity purified

Immunogen: E.coli-derived human RECK recombinant protein (Position: Q179-K806) was used as the immunogen for the RECK antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the RECK antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the RECK antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details for RECK

Target: RECK (Reversion-Inducing-Cysteine-Rich Protein with Kazal Motifs (RECK))

Alternative Name: RECK

Background: RECK antibody detects Reversion-inducing cysteine-rich protein with Kazal motifs, a membrane-anchored glycoprotein that negatively regulates matrix metalloproteinases (MMPs) and suppresses tumor invasion and angiogenesis. The UniProt recommended name is Reversion-inducing cysteine-rich protein with Kazal motifs (RECK). This protein acts as an extracellular matrix (ECM) regulator that maintains tissue integrity and prevents metastasis by inhibiting proteolytic remodeling.

Functionally, RECK antibody identifies a 971-amino-acid glycosylphosphatidylinositol (GPI)-anchored protein expressed on the cell surface. RECK directly inhibits MMP2, MMP9, and MMP14, limiting ECM degradation and tumor cell invasion. It also stabilizes tissue inhibitors of metalloproteinases (TIMPs) and modulates Notch and Wnt signaling pathways involved in development and tumor suppression. RECK expression is tightly controlled by transcriptional regulators and epigenetic mechanisms, including promoter methylation and microRNA repression.

The RECK gene is located on chromosome 9p13.3 and is broadly expressed in embryonic and adult tissues, including brain, lung, and vascular endothelium. High expression is associated with normal tissue homeostasis and morphogenesis, whereas silencing occurs in many cancers, correlating with poor prognosis.

Pathologically, RECK downregulation promotes cancer metastasis, vascular invasion, and inflammation by unleashing matrix-degrading enzymes. Conversely, forced expression of RECK inhibits tumor angiogenesis and cell migration. RECK deficiency also impairs embryonic vascular development, reflecting its essential role in morphogenesis. Research using RECK antibody supports studies in oncology, extracellular matrix biology, and developmental signaling.

RECK antibody is validated for western blotting, immunohistochemistry, and flow cytometry to detect MMP regulators. NSJ Bioreagents provides RECK antibody reagents optimized for research in metastasis inhibition, angiogenesis, and extracellular matrix control.

Structurally, Reversion-inducing cysteine-rich protein with Kazal motifs contains multiple cysteine-rich and Kazal-type serine protease inhibitor domains that confer high affinity for MMP catalytic sites. Its GPI anchor tethers it to the plasma membrane, positioning RECK for local ECM modulation. This antibody enables exploration of RECK's tumor-suppressive mechanisms and its role in cell-matrix interactions.

UniProt: O95980